10-Q: Predictive Oncology Faces Delisting, Pursues Capital Amid Losses

Predictive Oncology Inc. reports continued significant losses, faces Nasdaq delisting, and is pursuing multiple capital raises and a reverse stock split to maintain operations and listing.

Summary

• Net loss from continuing operations for the three months ended June 30, 2025, was $(1,978,895), an improvement from $(2,456,669) in the comparable 2024 period.
• Net loss from continuing operations for the six months ended June 30, 2025, was $(4,264,311), an improvement from $(6,020,774) in the comparable 2024 period.
• Total net loss for the three months ended June 30, 2025, was $(2,070,462), compared to $(3,181,261) in the prior year period.
• Total net loss for the six months ended June 30, 2025, was $(4,513,335), compared to $(7,400,104) in the prior year period.
• Revenue from continuing operations for the three months ended June 30, 2025, decreased significantly to $2,682 from $67,255 in the comparable 2024 period.
• Revenue from continuing operations for the six months ended June 30, 2025, increased to $112,992 from $72,113 in the comparable 2024 period.
• The company had an accumulated deficit of $184,939,606 as of June 30, 2025.
• Cash and cash equivalents stood at $506,078 as of June 30, 2025.
• Negative cash flows from continuing operating activities were $(4,280,632) for the six months ended June 30, 2025.
• The former Eagan operating segment was sold for $625,000 in March 2025.
• The company received a Nasdaq delisting notice on June 9, 2025, for non-compliance with the minimum stockholders' equity requirement ($2.5 million).
• A Nasdaq non-compliance notice for the minimum bid price ($1.00 per share) was received on July 8, 2025.
• Nasdaq granted an extension until December 8, 2025, to regain compliance with all listing requirements.
• A 1-for-15 reverse stock split is proposed, subject to stockholder approval.
• A Standby Equity Purchase Agreement (SEPA) was entered into with Yorkville on July 1, 2025, allowing the company to sell up to $10 million in common stock.
• Renovaro Inc. filed a lawsuit against the company on May 8, 2025, following the termination of merger discussions.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by recurring significant losses, an accumulated deficit of over $184 million, and a 'going concern' warning. Revenue from its continuing operations is minimal and declining in the most recent quarter. The company is actively seeking substantial capital through highly dilutive equity offerings and is proposing a 1-for-15 reverse stock split, which often signals deep underlying issues and can negatively impact investor sentiment and liquidity. The Nasdaq delisting notices for both stockholders' equity and minimum bid price, despite a temporary extension, highlight significant compliance challenges. Furthermore, the ongoing lawsuit with Renovaro adds legal and financial uncertainty. Given these compounding negative factors, the risk to shareholders is exceptionally high, and the probability of a sustained recovery appears low in the near term.

Positives

• Net loss from continuing operations decreased for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating some cost control.
• Successfully sold the Eagan operating segment assets for $625,000, providing a cash inflow and streamlining operations.
• Secured a Standby Equity Purchase Agreement (SEPA) for up to $10 million in potential equity financing, offering a source of future capital.
• Nasdaq granted an extension until December 8, 2025, to regain compliance with listing standards, temporarily averting delisting.
• General and administrative expenses decreased by $446,983 for the six months ended June 30, 2025, compared to 2024, primarily due to reduced consultant fees, audit fees, business taxes, and employee compensation.
• Operations, research and development expenses decreased by $168,656 for the six months ended June 30, 2025, compared to 2024, mainly due to decreased headcount and consultant fees.
• Sales and marketing expenses decreased by $470,304 for the six months ended June 30, 2025, compared to 2024, primarily due to lower employee compensation and headcount reductions.
• Recorded significant other income of $685,852 for the six months ended June 30, 2025, primarily from the write-off of aged accounts payable and related accrued expenses.

Negatives

• The company has incurred significant and recurring losses from operations for several years, with an accumulated deficit of $184,939,606 as of June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern within one year.
• Cash and cash equivalents of $506,078 as of June 30, 2025, are insufficient to meet operating needs.
• Current liabilities ($3,845,439) significantly exceed total current assets ($1,223,394) as of June 30, 2025.
• Revenue from continuing operations decreased dramatically in the three months ended June 30, 2025, to $2,682 from $67,255 in the prior year period.
• The company received a Nasdaq delisting notice on June 9, 2025, for failing to meet the minimum stockholders' equity requirement of $2.5 million.
• The company received a Nasdaq non-compliance notice on July 8, 2025, for its common stock bid price closing below $1.00 for 30 consecutive business days.
• Renovaro Inc. filed a lawsuit against the company on May 8, 2025, alleging breaches of contract related to the terminated merger discussions.
• A proposed 1-for-15 reverse stock split indicates severe share price weakness and potential for further negative investor sentiment and liquidity issues.
• Gross profit for the three months ended June 30, 2025, was a loss of $(15,539).

Risks

• Inability to continue operating beyond twelve months without additional financing.
• Continued negative operating cash flows.
• Capital needs to accomplish goals, including highly dilutive financing with potentially onerous terms.
• Inability to regain compliance with Nasdaq continued listing standards (stockholders' equity and minimum bid price) within the required timeframe.
• Risks related to recent and future acquisitions, including the benefits and costs of acquisition.
• Risks related to partnerships with other companies, including the need to negotiate definitive agreements, possible failure to realize anticipated benefits, and costs of providing funding.
• Inability to protect intellectual property or claims of infringing on others' intellectual property.
• Impact of competition in the oncology drug discovery market.
• Acquisition and maintenance of any necessary regulatory clearances for technology applications.
• Inability to attract or retain qualified senior management personnel, including sales and marketing personnel.
• Risk of never becoming profitable if products and services are not accepted by potential customers.
• Possible impact of government regulation and scrutiny.
• Unexpected costs and operating deficits, and lower than expected sales and revenues.
• Adverse results of any legal proceedings, specifically the Renovaro lawsuit.
• Volatility of operating results and financial condition.
• Challenges in managing growth.
• Business and operations could be materially and adversely affected by disruptions caused by economic and geopolitical uncertainties, as well as epidemics or pandemics.
• Uncertain impact of a reverse stock split on the future market price of common stock and the ability to maintain Nasdaq listing.
• Pursuing alternatives for additional funding could change the nature of the business and investment, potentially leading to a decline in share value or total loss of investment.

Future Outlook

The company continues to evaluate alternatives to obtain the required additional funding to maintain future operations, which may include equity financing, issuing debt, entering into other financing arrangements, or monetizing operating businesses or assets. There is no guarantee that sufficient operating revenue will be generated or that profitability will be achieved in the near term. The company is actively pursuing actions to satisfy Nasdaq listing requirements, including continued sales of common stock through its at-the-market offering, utilizing the Standby Equity Purchase Agreement (SEPA), expanding its ChemoFx drug response assay and business collaborations, and proposing a 1-for-15 reverse stock split. The company intends to file a definitive proxy statement and hold a special meeting of stockholders as soon as practicable to seek approval for the reverse stock split and the issuance of SEPA shares in excess of the Exchange Cap.

Management Comments

• We believe that we can improve the probability of success of advancing pharmaceutical and biological drug candidates with a higher degree of confidence.
• We do not believe the lawsuit has merit and continues to contest it vigorously.
• We are pursuing several actions to timely satisfy the terms of the Panels decision; however, there can be no assurance that we will be able to do so.

Industry Context

Predictive Oncology operates in the knowledge-driven oncology drug discovery and development sector, leveraging artificial intelligence (AI) and a proprietary biobank of tumor samples to provide insights for drug compounds and create tumor-specific 3D cell culture models. The company's focus is on improving the drug discovery process and increasing the probability of success for oncology drug candidates. The filing does not provide specific details on broader industry trends or direct comparisons to competitors, focusing instead on the company's internal operational and financial challenges.

Corporate Governance

Legal Proceedings

• On May 8, 2025, Renovaro Inc. filed a lawsuit in Delaware Chancery Court claiming breaches by the company of the Letter of Intent (LOI) and Extension Agreement related to a proposed merger, seeking to compel the company to enter into a merger agreement. The company does not believe the lawsuit has merit and is contesting it vigorously.

Stakeholder Impact

• **Shareholders:** Face significant dilution from multiple recent and planned equity raises (Registered Direct Offering, Renovaro subscription, Private Placement, ATM, SEPA). There is a high risk of further dilution from the proposed 1-for-15 reverse stock split. The ongoing Nasdaq delisting threats for both stockholders' equity and minimum bid price pose a risk to the liquidity and marketability of their investment. The 'going concern' warning indicates a potential for total loss of investment if the company cannot secure adequate funding.
• **Employees:** The company has experienced decreased headcount, as indicated by lower employee compensation in general and administrative, operations, research and development, and sales and marketing expenses, suggesting potential job insecurity or restructuring.
• **Creditors:** The company's precarious financial position and 'going concern' warning indicate a risk of default on existing payment obligations if additional financing is not secured.

Next Steps

• Regain compliance with Nasdaq listing standards (stockholders' equity and minimum bid price) by December 8, 2025.
• Hold a special meeting of stockholders to approve a 1-for-15 reverse stock split.
• Seek stockholder approval for the issuance of up to $10 million of common stock pursuant to the SEPA in order to sell shares in excess of the Exchange Cap.
• Continue sales of common stock through the At-The-Market offering program.
• Expand availability of the live cell ChemoFx drug response assay and business collaborations.
• Vigorously contest the lawsuit filed by Renovaro Inc. in Delaware Chancery Court.
• Evaluate alternatives to obtain additional funding to maintain future operations, including equity financing, debt, or asset monetization.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring significant losses, an accumulated deficit of over $184 million, and a 'going concern' warning. Revenue from its continuing operations is minimal and declining in the most recent quarter. The company is actively seeking substantial capital through highly dilutive equity offerings (ATM, SEPA) and is proposing a 1-for-15 reverse stock split, which often signals deep underlying issues and can negatively impact investor sentiment and liquidity. The Nasdaq delisting notices for both stockholders' equity and minimum bid price, despite a temporary extension, highlight significant compliance challenges. Furthermore, the ongoing lawsuit with Renovaro adds legal and financial uncertainty. Given these compounding negative factors, the risk to shareholders is exceptionally high, and the probability of a sustained recovery appears low in the near term.

Keywords

Predictive Oncology, POAI, AI in oncology, cancer therapies, drug discovery, biobank, 3D cell culture models, Nasdaq delisting, reverse stock split, equity financing, going concern, Renovaro lawsuit, biotechnology, pharmaceuticals